Editorial: Therapeutic management of COVID-19 in immunocompromised patients and interaction with the immune response: from preventive to curative strategies.
作者信息
Benotmane Ilies, Solis Morgane
机构信息
Département de Néphrologie-Dialyse-Transplantation, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
Laboratoire de Virologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
出版信息
Front Immunol. 2024 Jul 16;15:1441199. doi: 10.3389/fimmu.2024.1441199. eCollection 2024.
Abstract
摘要
相似文献
1
Editorial: Therapeutic management of COVID-19 in immunocompromised patients and interaction with the immune response: from preventive to curative strategies.社论：免疫功能低下患者新冠病毒病的治疗管理及其与免疫反应的相互作用：从预防到治疗策略
Front Immunol. 2024 Jul 16;15:1441199. doi: 10.3389/fimmu.2024.1441199. eCollection 2024.
2
Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial.为免疫功能低下人群优化 COVID-19 疫苗接种方案（BOOST-IC）：一项适应性随机对照临床试验的研究方案。
Trials. 2024 Jul 17;25(1):485. doi: 10.1186/s13063-024-08315-2.
3
Improved immunogenicity against SARS-CoV-2 in a solid-organ transplant recipient by switching vaccines.通过更换疫苗提高实体器官移植受者对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的免疫原性。
Clin Microbiol Infect. 2021 Oct;27(10):1529-1530. doi: 10.1016/j.cmi.2021.06.022. Epub 2021 Jun 27.
4
Effect of antimetabolite regimen on cellular and humoral immune response to SARS-COV-2 vaccination in solid organ transplant recipients.抗代谢药物方案对实体器官移植受者接种 SARS-CoV-2 疫苗后细胞和体液免疫应答的影响。
Immunol Lett. 2024 Aug;268:106886. doi: 10.1016/j.imlet.2024.106886. Epub 2024 Jun 19.
5
The Immunology of SARS-CoV-2 Infection and Vaccines in Solid Organ Transplant Recipients.实体器官移植受者中 SARS-CoV-2 感染和疫苗的免疫学
Viruses. 2021 Sep 20;13(9):1879. doi: 10.3390/v13091879.
6
Outpatient treatment with concomitant vaccine-boosted convalescent plasma for patients with immunosuppression and COVID-19.免疫抑制患者 COVID-19 的门诊治疗与疫苗加强恢复期血浆治疗。
mBio. 2024 May 8;15(5):e0040024. doi: 10.1128/mbio.00400-24. Epub 2024 Apr 11.
7
What is the immunological response to BNT162b2 mRNA vaccine in immunocompromised patients?免疫功能低下患者对BNT162b2 mRNA疫苗的免疫反应是什么？
EBioMedicine. 2021 Dec;74:103733. doi: 10.1016/j.ebiom.2021.103733. Epub 2021 Dec 1.
8
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial.在一项前瞻性、开放性标签临床试验中，评估了 mRNA BNT162b2 疫苗在五组免疫功能低下患者和健康对照者中的安全性和有效性。
EBioMedicine. 2021 Dec;74:103705. doi: 10.1016/j.ebiom.2021.103705. Epub 2021 Nov 30.
9
Monoclonal Antibodies for COVID-19 Preexposure Prophylaxis Can't Come Fast Enough for Some People.对于一些人来说，用于新冠病毒暴露前预防的单克隆抗体来得不够快。
JAMA. 2021 Nov 16;326(19):1895-1897. doi: 10.1001/jama.2021.19534.
10
Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration.肾移植受者在首次接种新冠疫苗后很少出现早期抗体反应。
Transplantation. 2021 Jul 1;105(7):e72-e73. doi: 10.1097/TP.0000000000003764.
引用本文的文献
1
Immunological Enigma: A Case Report of COVID-19 Survival in a Patient With Human Immunodeficiency Virus, Hepatitis C Virus, and Tuberculosis Co-infection.免疫之谜：一例人类免疫缺陷病毒、丙型肝炎病毒和结核病合并感染的COVID-19患者存活病例报告。
Cureus. 2024 Sep 17;16(9):e69588. doi: 10.7759/cureus.69588. eCollection 2024 Sep.
本文引用的文献
1
Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.COVID-19 患者接受奈玛特韦/利托那韦联合免疫抑制剂治疗时的免疫抑制剂剂量调整适应策略。
Transpl Int. 2024 Mar 26;37:12360. doi: 10.3389/ti.2024.12360. eCollection 2024.
2
Excess mortality in COVID-19-affected solid organ transplant recipients across the pandemic.大流行期间 COVID-19 影响的实体器官移植受者的超额死亡率。
Am J Transplant. 2024 Aug;24(8):1495-1508. doi: 10.1016/j.ajt.2024.03.016. Epub 2024 Mar 20.
3
Longitudinal analysis of serum neutralization of SARS-CoV-2 Omicron BA.2, BA.4, and BA.5 in patients receiving monoclonal antibodies.接受单克隆抗体治疗的患者体内血清对 SARS-CoV-2 奥密克戎 BA.2、BA.4 和 BA.5 的中和作用的纵向分析。
Cell Rep Med. 2022 Dec 20;3(12):100850. doi: 10.1016/j.xcrm.2022.100850. Epub 2022 Nov 17.
4
Efficacy of anti-SARS-CoV-2 monoclonal antibody prophylaxis and vaccination on the Omicron variant of COVID-19 in kidney transplant recipients.抗SARS-CoV-2单克隆抗体预防和疫苗接种对肾移植受者中新冠病毒奥密克戎变异株的疗效
Kidney Int. 2022 Aug;102(2):440-442. doi: 10.1016/j.kint.2022.05.007. Epub 2022 May 23.
5
Early Administration of Anti-SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients.早期给予抗SARS-CoV-2单克隆抗体可预防肾移植患者发生重症新型冠状病毒肺炎。
Kidney Int Rep. 2022 Jun;7(6):1241-1247. doi: 10.1016/j.ekir.2022.03.020. Epub 2022 Mar 26.
6
A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients.mRNA-1273新冠病毒疫苗的第四剂增强了肾移植受者血清对德尔塔变异株的中和作用。
Kidney Int. 2022 May;101(5):1073-1076. doi: 10.1016/j.kint.2022.02.011. Epub 2022 Feb 26.
Zotero 插件